Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
申请人:Taniguchi Takahiko
公开号:US09150588B2
公开(公告)日:2015-10-06
A compound having PDE inhibitory represented by formula (1), W1-W2 (1), wherein (i) W1 is
and W2 is
(ii) W1 is
and W2 is
or (iii) W1 is
and W2 is
or a pharmaceutically acceptable salt thereof; and a method of treating or preventing schizophrenia.
HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A
申请人:Takeda Pharmaceutical Company Limited
公开号:EP2604597B1
公开(公告)日:2017-01-04
US9150588B2
申请人:——
公开号:US9150588B2
公开(公告)日:2015-10-06
HETEROCYCLIC COMPOUND AND USE THEREOF
申请人:Taniguchi Takahiko
公开号:US20130137675A1
公开(公告)日:2013-05-30
The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like.
A compound represented by the formula (1
x
):
wherein each symbol is as described in the DESCRIPTION, or the formula (1):
W
1
—W
2
(1)
wherein each symbol is as described in the DESCRIPTION,
or a salt thereof.